Key strengths

Driving future growth

We believe our future growth will be driven by the following competitive strengths:


Broad portfolio and deep expertise in cell engineering.

We believe we are a leader in leveraging technologies in gene editing and gene modulation with a proven ability to develop and commercialise them in our markets. We have access to a variety of cell engineering technologies, which allows us to take a technology agnostic approach to delivering customer solutions.


Attractive, large and high growth addressable end markets.

Our portfolio of gene editing and gene modulation tools and services support and enable critical elements of the therapeutic ecosystem, from basic research through to drug discovery and development and therapeutic applications.


Established commercial team with global reach led by an experienced management team.

We have an experienced senior management team whose members have a proven track record of growing successful global life science tools and services businesses and experience in industrialising, scaling and commercialising biological tools and services. We believe our 40-person sales organisation, comprising key account partners, territory sales and field application specialists, provides us with global reach, and is a key differentiator.


High growth business comprising a mix of well-established and potentially disruptive business units.

Our business is underpinned by our long standing, high growth Research Reagents business which generated over 70% of our revenues in 2019, generated from over a thousand customers in the U.S. and worldwide.


Unique market insights derived from longstanding customer relationships.

We have established deep customer relationships with leading academic institutes and biopharmaceutical and diagnostics companies globally. The insights we gain from these customer relationships inform our product development and ensure that our tools and services are aligned to customers’ needs.

“As a result of the changes we have made to the business over the last 12 months, Horizon has never been better placed to capitalise on its unique market position.”

Ian Gilham

Non-Executive Chairman